Rheumatoid arthritis

Rheumatoid arthritis is a chronic inflammatory joint disease. Study layers here separate three claims: a RIPK1 inhibitor experimental-medicine RCT without meaningful mean efficacy at tested exposures, a phase 1b MTD for a fibroblast-aimed CDK inhibitor in TNF-refractory disease, and early synovial biopsy evidence of molecular/histologic heterogeneity.

Students meet “new RA targets” as one pipeline story. A null RIPK1 efficacy signal, a seliciclib dose-finding result, and early synovium clusters answer different development questions. Mixing them invents false agreement about what works.

Claim ledger

What the evidence shows

Drawn from 3 studies in this library. Mix labels say which citation roles are present; they are not a strength score. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope.

• ○ Limited citations

  GSK2982772 (RIPK1) looked similar to placebo on RA activity at tested exposures.

  In a 52-patient placebo-controlled experimental-medicine study on stable csDMARDs, safety was primary and DAS28-CRP/ACR outcomes were similar between GSK2982772 and placebo — authors conclude no meaningful clinical improvement at evaluated exposures.

  1 supporting · 2 qualifying

  Supports

  1. 1RIPK1 inhibitor GSK2982772 did not beat placebo on RA activity here

  Qualifies

  1. 1Seliciclib MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b)— different development stage/target — open-label MTD for a CDK/fibroblast strategy, not RIPK1 efficacy
  2. 2Early RA synovium splits into two expression/histology groups— tissue heterogeneity biology, not a drug RCT

  Study comparison

  Study	Role	Design	N	Population	Outcome
  RIPK1 inhibitor GSK2982772 did not beat placebo on RA activity here2021	Supports	RCTMulticenter double-blind placebo-controlled experimental-medicine RCT; 2:1 drug:placebo for 84 days on stable csDMARD	N=52 · 34 GSK2982772 60 mg, 18 placebo	Adults with rheumatoid arthritis on stable conventional DMARD therapy	Safety/PK and preliminary DAS28-CRP / ACR efficacy
  Seliciclib MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b)2021	Qualifiesdifferent development stage/target — open-label MTD for a CDK/fibroblast strategy, not RIPK1 efficacy	Human experimentPhase 1b TRAFIC: non-randomised open-label Bayesian dose-finding of oral seliciclib	N=15 · Five dose cohorts; MTD 400 mg at 35% DLT target	Adults with active RA despite ≥3 months stable anti-TNF therapy	Maximum tolerated dose (dose-limiting toxicity)
  Early RA synovium splits into two expression/histology groups2005	Qualifiestissue heterogeneity biology, not a drug RCT	OtherArthroscopic targeted synovial biopsy histopathology + expression clustering	N=16 · 12 early RA (<1 year) and 4 long-standing RA; 18 samples from 16 cases	Adults with early or long-standing rheumatoid arthritis undergoing targeted synovial biopsy	Histopathology and gene-expression subgroups of synovitis

• ○ Limited citations

  Seliciclib’s MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b).

  In 15 open-label patients with active RA despite TNF inhibitors, Bayesian dose-finding set seliciclib MTD at 400 mg, aiming at synovial fibroblast proliferation rather than classic immune-cytokine pathways alone.

  1 supporting · 1 qualifying

  Supports

  1. 1Seliciclib MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b)

  Qualifies

  1. 1RIPK1 inhibitor GSK2982772 did not beat placebo on RA activity here— MTD ≠ efficacy; RIPK1 study tested clinical activity and was null at its exposures

  Study comparison

  Study	Role	Design	N	Population	Outcome
  Seliciclib MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b)2021	Supports	Human experimentPhase 1b TRAFIC: non-randomised open-label Bayesian dose-finding of oral seliciclib	N=15 · Five dose cohorts; MTD 400 mg at 35% DLT target	Adults with active RA despite ≥3 months stable anti-TNF therapy	Maximum tolerated dose (dose-limiting toxicity)
  RIPK1 inhibitor GSK2982772 did not beat placebo on RA activity here2021	QualifiesMTD ≠ efficacy; RIPK1 study tested clinical activity and was null at its exposures	RCTMulticenter double-blind placebo-controlled experimental-medicine RCT; 2:1 drug:placebo for 84 days on stable csDMARD	N=52 · 34 GSK2982772 60 mg, 18 placebo	Adults with rheumatoid arthritis on stable conventional DMARD therapy	Safety/PK and preliminary DAS28-CRP / ACR efficacy

• ○ Limited citations

  Early RA synovium already shows two expression/histology clusters.

  Targeted arthroscopic biopsies from early RA clustered into two major gene-expression groups with different histological scores — molecular heterogeneity early in disease, not a treatment-assignment tool by itself.

  1 supporting · 1 qualifying

  Supports

  1. 1Early RA synovium splits into two expression/histology groups

  Qualifies

  1. 1Seliciclib MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b)— fibroblast-targeting rationale is related thematically, but TRAFIC is dose-finding in TNF-refractory disease, not early-biopsy clustering

  Study comparison

  Study	Role	Design	N	Population	Outcome
  Early RA synovium splits into two expression/histology groups2005	Supports	OtherArthroscopic targeted synovial biopsy histopathology + expression clustering	N=16 · 12 early RA (<1 year) and 4 long-standing RA; 18 samples from 16 cases	Adults with early or long-standing rheumatoid arthritis undergoing targeted synovial biopsy	Histopathology and gene-expression subgroups of synovitis
  Seliciclib MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b)2021	Qualifiesfibroblast-targeting rationale is related thematically, but TRAFIC is dose-finding in TNF-refractory disease, not early-biopsy clustering	Human experimentPhase 1b TRAFIC: non-randomised open-label Bayesian dose-finding of oral seliciclib	N=15 · Five dose cohorts; MTD 400 mg at 35% DLT target	Adults with active RA despite ≥3 months stable anti-TNF therapy	Maximum tolerated dose (dose-limiting toxicity)

Debates

Tensions and limits

Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes.

Timeline

How understanding moved

Study years are when the paper was published. Evidence edits are dated changes to this page's claims. Explanations are when PaperFren added a Discovery — not a claim that the science happened that day.

Papers

3 studies in this library bear on Rheumatoid arthritis, ordered by citations.

• RIPK1 inhibitor GSK2982772 did not beat placebo on RA activity here

  In 52 patients with moderate–severe RA on stable csDMARDs, oral GSK2982772 60 mg for 84 days was mainly assessed for safety; DAS28-CRP and ACR responses looked similar to placebo, without meaningful clinical improvement at tested exposures.

  Arthritis research & therapy · 2021 · 81 citations

• Seliciclib MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b)

  In an open-label UK dose-finding trial of 15 TNF-refractory RA patients, the CDK inhibitor seliciclib’s maximum tolerated dose was 400 mg, aiming at synovial fibroblast proliferation rather than classic immune-cytokine targets alone.

  The Lancet. Rheumatology · 2021 · 52 citations

• Early RA synovium splits into two expression/histology groups

  Targeted knee synovial biopsies from early RA patients clustered into two major gene-expression groups with different histological scores, showing molecular heterogeneity even early in disease.

  Arthritis research & therapy · 2005 · 52 citations

Questions

What is still open

1. A null RIPK1 activity signal, an MTD for seliciclib, and early synovium clusters are different evidence types. Pathway interest does not transfer efficacy across programmes.

   Watch this

Ask PaperFren about Rheumatoid arthritis